Design of a Phase 1, First‐in‐human, Randomized, Double‐blind, Placebo‐controlled, Single and Multiple Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG‐3927) in Healthy Volunteers
Raj Rajagovindan, Francois Gaudreault, Ryan O’Mara, Evan A Thackaberry, Jessica Stromme, David L Gray, Andreas Meier · 2025
Read Design of a Phase 1, First‐in‐human, Randomized, Double‐blind, Placebo‐controlled, Single and Multiple Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG‐3927) in Healthy Volunteers by Raj Rajagovindan, Francois Gaudreault, Ryan O’Mara, Evan A Thackaberry, Jessica Stromme, David L Gray, Andreas Meier (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712638.txt.
Description
Raj Rajagovindan and co-authors lay out the design of a first-in-human trial of a new pill for Alzheimer's disease. The study plan appeared in 2025. The pill turns up a switch on brain immune cells that helps them clean damage and heal tissue. Loss of that switch raises disease risk two to three-fold.
The trial will enroll healthy adults aged eighteen to fifty-five. Each dose group will hold eight people, with six on the pill and two on a dummy pill. Single doses come first for one day, then daily doses for two weeks. The team will track safety, how the body handles the pill, and early signs of action.
Catalog record
| CREATOR | Raj Rajagovindan, Francois Gaudreault, Ryan O’Mara, Evan A Thackaberry, Jessica Stromme, David L Gray, Andreas Meier |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |